Rate of Postoperative Delirium and Postoperative Cognitive Dysfunction After Spinal Anesthesia

September 9, 2022 updated by: Claudia Spies, Charite University, Berlin, Germany

Rate of Postoperative Delirium and Postoperative Cognitive Dysfunction After Spinal Anesthesia With Short-acting Local Anesthetics Compared to General Anesthesia After a Shared Decision Making Process

The aim of this investigation is to compare the standard of general anesthesia used in these patients with these short-acting local anesthetics (Chloroprocain (Ampres®) and Prilocain (Takipril®)) for spinal anesthesia as well as to report the patient centered outcome of postoperative delirium and neurocognitive disorder. In accordance to current evidence regarding the occurrence of postoperative delirium and postoperative cognitive deficit, patients are to be screened daily for delirium up to the fifth postoperative day if in hospital, or till the first postoperative day after ambulatory surgery and for neurocognitive disorder 1 year following the surgery. To detect delirium the Nu-DESC (Nursing Delirium Screening Scale) will be used as a validated scoring systems to ensure the highest sensitivity in delirium identification. CANTAB battery will be used for assessment of neurocognitive disorder. This is a neuropsychological testing (computer-based (I-Pad) [Cambridge Neuropsychological Test Automated Battery - CANTAB connect and parameters from the item list], as well as the subjective / by proxy Assessment of Cognitive Limitations. It is essential to perform the appropriate cognitive performance tests not only on operative patients but also on a non-surgical cohort, using currently established models of calculation in postoperative cognitive deficits and a control group generated from non-surgical patients.

Study Overview

Detailed Description

A conventional spinal anesthesia with long-acting drugs (such as bupivacaine) can lead to delays in postoperative recovery, mobilization, delays in discharge from recovery room and in ambulatory surgery. Short-acting local anesthetics (Chloroprocain (Ampres®) and Prilocain (Takipril®)) might be beneficial in short duration surgery under spinal anesthesia and could improve patients' acceptance for neuroaxial anesthesia as it might improve early recovery and early mobilization. Time to first oral nutritional intake/postoperative nausea and vomiting (PONV), time to discharge from post-anesthesia recovery unit and time to discharge home after ambulatory operation might be reduced and might reduce incidence of postoperative delirium and neurocognitive disorder after peripheral surgery.

It is planned to retrospectively examine a group of surgical patients for the purpose of a comparative descriptive collective. This comparison collective is required for various questions, in particular influencing factors with regard to the postoperative outcomes delirium, neurocognitive disorder and mortality. Only the routine data is used and no additional surveys are performed on these patients. Inclusion criteria such as the study cohort and additionally the inclusion criterion: Spinal anesthesia with another local anesthetic

Study Type

Observational

Enrollment (Actual)

237

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 10117
        • Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité - Universitätsmedizin Berlin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Surgical patients at Campus Virchow - Klinikum and Campus Charité Mitte (Charité - Universitätsmedizin Berlin) with short, elective procedure (<90 minutes), feasible in spinal anesthesia

Description

Study group 1 and 2

Inclusion Criteria:

  • Surgical patients at Campus Virchow - Klinikum and Campus Charité Mitte (Charité - Universitätsmedizin Berlin)
  • Short, elective procedure (<90 minutes), feasible in spinal anesthesia
  • American Society of Anesthesiologists (ASA-Score I to III)
  • Age ≥ 18 years
  • Informed consent process

Exclusion Criteria:

  • Non-consenting patients
  • Lack of consent to participate in the study or to store, process and disseminate pseudonymised study data
  • Allergy or contraindications to local anesthetics
  • Contraindications to spinal anesthesia
  • Coagulopathy or therapy with anticoagulants
  • Higher grade aortic stenosis
  • Anomaly of the spinal cord
  • Pre-existing neurological deficit
  • Pre-existing neurological disease that severely limits the performance of neurocognitive testing
  • Hearing and / or visual disturbances (such as color blindness) or relevant language barrier severely limiting the performance of neurocognitive testing
  • Spinal anesthesia with another local anesthetic
  • Sole peripheral local anesthesia
  • Participation in another prospective intervention study
  • Emergency operation
  • Pregnancy and breast feeding period

POCD Control group:

Inclusion criteria:

  • Male and female patients ages 18-100 years, also controls from the POCD registry (EA1/104/16)
  • Healthy volunteers (ASA I) / ASA II + III patients who are not scheduled for surgery next year
  • Ability to consent to oral and written information
  • Patient education and written consent

Exclusion criteria:

  • Operation in the last six months before inclusion in this study
  • Lack of consent for the pseudonymised disease data to be stored and shared in this clinical trial
  • Lack of readiness to participate in the follow-up examinations and contact to make an appointment
  • Patients with a neuropsychiatric condition that limits the performance of neurocognitive testing
  • Patients with hearing and / or vision disorders or relevant language barriers that limit the performance of neuro-cognitive testing
  • Simultaneous participation in a prospective clinical intervention study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Study group 1
n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
Spinal anesthesia in patients with duration of surgery < 90 minutes
Study group 2
n= 220 patients for routine data of general anesthesia (current standard)
General anesthesia in patients with duration of surgery < 90 minutes
No intervention: Control group postoperative cognitive deficit
n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of postoperative delirium
Time Frame: Up to five postoperative days
Postoperative delirum rate, defined according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V) and/or as ≥ 2 cumulative points in the nursing Delirium Screening Scale (Nu-DESC) and/or a positive Confusion Assessment Method (CAM) Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score and/or patient chart review that shows descriptions of delirium. The basis is the elevation of the sedation depth with the Richmond Agitation Sedation Scale (RASS).
Up to five postoperative days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative cognitive disturbances
Time Frame: Up to 1 year
Cognitive disorders are evaluated according to DSM-V (formal cognitive testing, subjective memory sensing and instrumental activities of daily living, ).
Up to 1 year
MONTREAL COGNITIVE ASSESSMENT (MOCA)
Time Frame: Up to 1 year
Test performance of the MONTREAL COGNITIVE ASSESSMENT (MOCA) for screening of dementia
Up to 1 year
Formal cognitive testing
Time Frame: Up to 1 year
Perioperative changes of damain specific test performance in formal cognitive testing
Up to 1 year
Postoperative cognitive dysfunction (POCD)
Time Frame: Up to 1 year
Postoperative cognitive dysfunction (POCD) is measured by computerized Cambridge Neuropsychological Test Automated Battery - CANTAB connect and paper pencil testing and subjective memory sensing.
Up to 1 year
Duration of delirium
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) Nursing Delirium Screening Scale (Nu-DESC) Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) Confusion Assessment Method (CAM) Chart Review
Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Severity of delirium
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) Nursing Delirium Screening Scale (Nu-DESC), Confusion Assessment Method (CAM) and or Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), Chart Review
Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Time to mobilization
Time Frame: Up to five postoperative days
Up to five postoperative days
Time to first oral nutritional intake
Time Frame: Up to five postoperative days
Up to five postoperative days
Time until leaving the recovery room
Time Frame: Up to leaving the recovery room
Fulfillment of discharge criteria from the recovery room
Up to leaving the recovery room
Time until leaving hospital
Time Frame: Up to five postoperative days
Fulfillment of discharge criteria from hospital after study procedure
Up to five postoperative days
Organ complications according to Clavien
Time Frame: Up to five postoperative days
Up to five postoperative days
Autonomy Preference Index (API)
Time Frame: Up to five postoperative days
Up to five postoperative days
Questionnaire for shared decision making (PEF-FB-9)
Time Frame: Up to five postoperative days
Results from PEF-FB-9 are evaluated
Up to five postoperative days
Total treatment outcome in terms of quality of life of patients
Time Frame: Up to 1 year
EQ-5D
Up to 1 year
Total treatment outcome in terms of functional autonomy of patients
Time Frame: Up to 1 year
Activities of Daily Living (ADLs) or Instrumental Activities of Daily Living (IADLs)
Up to 1 year
Intraoperative Neuromonitoring
Time Frame: Up to the end of surgical procedure
Up to the end of surgical procedure
Cerobrospinal fluid parameter
Time Frame: Until the end of surgery
Beta-Amyloid 1-40, beta-Amyloid 1-42, beta-Amyloid Ratio (42/40*10), phospho-TAU, Protein 14-3-3, PRPSc, TAU (Gesamt-Tau) from cerobrospinal fluid for measuring dementia
Until the end of surgery
Apolipoprotein E
Time Frame: Until the end of surgery
Blood marker Apolipoprotein E for measuring dementia
Until the end of surgery
Multiplex Gene Expression Analysis (Whole Blood)
Time Frame: Until first postoperative day
Until first postoperative day
Antibodies
Time Frame: Until first postoperative day
Antibody from serum (anti-beta2-adrenergic receptor, anti-muscarinic acetylcholine receptor (M3 / M4), anti-serotonin receptor, anti-dopamine receptor)
Until first postoperative day
Pro and anti-inflammatory markers
Time Frame: Until first postoperative day
IL-8 from whole blood and IL-6, IL-8 and TGF
Until first postoperative day
Immune cells
Time Frame: Until first postoperative day
Immune cells from citrate blood
Until first postoperative day
Autophagy of platelets
Time Frame: Until first postoperative day
Autophagy of platelets from citrate blood
Until first postoperative day
Intracellular pH
Time Frame: Until first postoperative day
Intracellular pH from citrate blood
Until first postoperative day
Cholinesterases
Time Frame: Until the third postoperative day
Until the third postoperative day
Anxiety 1
Time Frame: Up to 1 year
Anxiety 1 is measured by Generalized Anxiety Disorder 7 (GAD-7) and Patient Health Questionnaire 9 (PHQ-9)
Up to 1 year
Anxiety 2
Time Frame: Up to 1 year
Anxiety 2 is measured by Amsterdam Preoperative Anxiety and Information Scale (APAIS) and Faces Anxiety Scale (FAS)
Up to 1 year
Subsequent surgery
Time Frame: Up to 1 year
Results from subsequent surgery are evaluated
Up to 1 year
Obstructive Sleep Apnea (OSAS)
Time Frame: Up to 1 year
Obstructive Sleep Apnea (OSAS) is measured by the STOP-Bang Questionnaire.
Up to 1 year
Fatigue
Time Frame: Up to 1 year
Fatigue is monitored by Acute Fatigue Score
Up to 1 year
Sleep behavior
Time Frame: Up to 1 year
Sleep behaviour is measured by Insomnia Severity Index (ISI) at baseline, 3 months, 1 year
Up to 1 year
Sleep behavior
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Sleep behaviour is measured by intraclinical course (immediate perioperative: Richards Campbell Sleep Questionnaire)
Participants will be followed for the duration of hospital stay, an expected average of 7 days ]
Frailty
Time Frame: Participants will be measured at the beginning of the investigation.
Frailty is measured with a modified frailty score according to Fried´s frailty phenotype assessment
Participants will be measured at the beginning of the investigation.
Stress
Time Frame: Up to 1 year
Stress is monitored by Perceived Stress Questionnaire 20 (PSQ20) and Disstressthermometer without areas
Up to 1 year
Dose of concomitant medication
Time Frame: Up to 5 postoperative days
The types of medications used in the management of pain, agitation, and delirium on that day are documented.
Up to 5 postoperative days
Duration of concomitant medication
Time Frame: Up to 5 postoperative days
The types of medications used in the management of pain, agitation, and delirium on that day are documented.
Up to 5 postoperative days
Time of mechanical ventilation
Time Frame: Participants will be followed for the duration of intensive care unit stay, an expected average of 1 day]
Participants will be followed for the duration of intensive care unit stay, an expected average of 1 day]
Intensive care unit stay
Time Frame: Participants will be followed for the duration of intensive care unit stay, an expected average of 1 day]
Participants will be followed for the duration of intensive care unit stay, an expected average of 1 day]
Number of stationary recoveries
Time Frame: Up to 1 year
Up to 1 year
Visits to doctors and outpatient treatments
Time Frame: Up to 1 year
Up to 1 year
Number of additional operations
Time Frame: Up to 1 year
Up to 1 year
Mortality
Time Frame: Up to 1 year
Up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 12, 2019

Primary Completion (Actual)

November 9, 2021

Study Completion (Actual)

July 14, 2022

Study Registration Dates

First Submitted

October 9, 2018

First Submitted That Met QC Criteria

October 18, 2018

First Posted (Actual)

October 23, 2018

Study Record Updates

Last Update Posted (Actual)

September 14, 2022

Last Update Submitted That Met QC Criteria

September 9, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on Spinal anesthesia with short-acting local anesthetics

3
Subscribe